Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Biotechnology

Healthcare
$0.90 +3.01%

+$0.06 today

Market cap
$54.28M
Beta
1.19
P/E (TTM)
-4.2
EPS (TTM)
-$0.45
52W Low $1.07High $6.18

Volume 1.45M

Average 2.13M

ALDX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Aldeyra Therapeutics, Inc.NASDAQ: ALDX

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash grows, but more slowly than its trailing trend

Q1 FY2026 net change in cash of $5.04M (cash outflow) rose 20.7% year over year, behind the +134.8% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +20.7% toward the trailing-twelve-month pace of +134.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.04M-147.1% QoQ
Last fiscal yearDec 2025
$15.51M+117.6% YoY
LTMMar 2026
$14.65M+134.8% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.7%——
1 year+117.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
15.51M USD
Year-over-year change
+117.6%
4-year CAGR
-43.5%

Net Change in Cash vs competitors

How ALDX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +134.8% is the 2nd highest of 10, against a peer median of -85.3%.
ALDX Competitors
Net Change in Cash for ALDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANROAlto Neuroscience, Inc.LTM Mar 2026$103.01M USD+330.7%-28.6%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$102.82M USD+54.7%——
CLLSCellectis S.A.LTM Mar 2026$94.68M USD-2129.6%-4.8%139.1%
SLNSilence Therapeutics plcLTM Mar 2026$59.21M USD—+49.3%6425.7%
MREOMereo BioPharma Group plcLTM Mar 2026$26.26M USD-290.0%-21.3%5252.0%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$24.68M USD-85.3%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$14.65M USD+134.8%——
AMRNAmarin Corporation plcLTM Mar 2026$11.44M USD+112.1%—5.3%
ACIUAC Immune S.A.LTM Dec 2025CHF 9.36M CHF-77.8%-54.0%262.0%
GNLXGenelux CorporationLTM Mar 2026$6.93M USD-157.1%-7.6%86662.5%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$2.31M USD-137.3%+285.2%—
Peer median (excluding ALDX) —-85.3%-7.6%2757.0%

Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Depreciation & Amortization264.18K258.71K262.78K249.62K251.99K
Deferred Income Tax00000
Stock-Based Compensation7.11M8.29M5.75M7.97M6.09M
Change in Working Capital7.44M(3.44M)861.18K5.91M(5.18M)
Accounts Receivables00000
Inventory00000
Accounts Payables638.06K(886.08K)1.2M(1.16M)(21.99K)
Other Working Capital6.8M(2.56M)(343.25K)7.07M(5.16M)
Other Non-Cash Items409.47K283.91K339.65K(1.49M)(664.43K)
Operating Cash Flow(42.56M)(56.64M)(30.33M)(43.21M)(33.35M)
Capital Expenditures(7.81K)(16.32K)000
Acquisitions (Net)016.32K000
Purchases of Investments0(92.94M)0(96.92M)(40.26M)
Sales of Investments063M30M52M88M
Other Investing Activities0(16.32K)000
Investing Cash Flow(7.81K)(29.95M)30M(44.92M)47.74M
Debt Repayment00(1.04M)(292.5K)0
Common Stock Issued189.81M1.22M305.23K121.08K1.12M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.68M0(532.95K)0(444)
Financing Cash Flow194.5M1.22M(1.27M)(171.42K)1.12M
Effect of Forex Changes00000
Net Change in Cash151.93M(85.37M)(1.6M)(88.3M)15.51M
Free Cash Flow(42.56M)(56.65M)(30.33M)(43.21M)(33.35M)

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.